Company: PHAT
Filing Date: 2025-04-23
Form Type: DEF 14A
Source: 0000950170-25-057326
Chunk: 42

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-04-23
Form: DEF 14A
Chunk 42
---
 exercisable within 60 days following April 7, 2025, 19,500 shares of common stock issuable to Dr. Topper upon the vesting of restricted stock units that have vested or are scheduled to vest within 60 days following April 7, 2025, 12,596 shares held directly by Dr. Topper, 3,912 shares held of record by Topper Group III LLC. and the securities described in footnote (1) above. Dr. Topper is a manager of Topper Group III LLC and has voting and investment power of the securities held by Topper Group III LLC.

Consists of the shares held by the executive officers and directors described in footnotes 5 through 14 above, excluding Ms. Curran, our former President and Chief Executive Officer who resigned in March 2025.

<div align='center'>27</div>

EXECUTIVE OFFICERS Our Executive Officers The following table sets forth the name, age and position of each of our executive officers as of April 23, 2025.

| Name                       |     | Age |    |     | Position                                        |
| Executive Officers         |     |     |    |     |                                                 |
| Steven Basta               |     |     | 59 |     | President, Chief Executive Officer and Director |
| Azmi Nabulsi, M.D., M.P.H. |     |     | 65 |     | Chief Operating Officer                         |
| Molly Henderson            |     |     | 54 |     | Chief Financial and Business Officer            |

Executive Officers The biography of Steven Basta can be found under “Proposal 1—Election of Directors.” Azmi Nabulsi, M.D., M.P.H. is our co-founder and has served as our Chief Operating Officer since March 2019. Dr. Nabulsi has been an entrepreneur-in-residence at Frazier since October 2018. Also, from March 2020 through 2023, Dr. Nabulsi served as a director of ReAlta Life Sciences, an early-stage biotechnology company, and from January 2019 through 2022, Dr. Nabulsi served as a business and clinical advisor to Saama Technologies, Inc., a clinical data and analytics company. Previously, through October 2018, Dr. Nabulsi spent fourteen years at Takeda. Dr. Nabulsi held several leadership positions at Takeda, most recently as the Deputy Chief Medical & Scientific Officer and